Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 3/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CTSL | P07711 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 1/20 | 0.60 |
| ▸ | CTSK | P43235 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | TLR4 | O00206 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclobutylcarbamic Acid Benzyl Ester SCHEMBL579215 | 0.98 | EPHX1 (0.74) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL7198149 | 0.97 | EPHX1 (0.81) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL8393719 | 0.95 | EPHX1 (0.84) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL1424064 | 0.95 | EPHX1 (0.84) | EPHX1ALDH1A1GAATSHRMEN1 | |
| Cyclobutylcarbamic Acid Benzyl Ester SCHEMBL29047875 | 0.94 | EPHX1 (0.73) | EPHX1ALDH1A1GAATSHRMEN1 | |
| Cyclobutylcarbamic Acid Benzyl Ester SCHEMBL27741202 | 0.94 | EPHX1 (0.69) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL328941 | 0.94 | EPHX1 (0.69) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL5442666 | 0.94 | EPHX1 (0.68) | EPHX1ALDH1A1GAATSHRMEN1 | |
| SCHEMBL5442669 | 0.94 | EPHX1 (0.68) | EPHX1ALDH1A1GAATSHRMEN1 | |
| Bicarbonate SCHEMBL6203780 | 0.94 | EPHX1 (0.82) | EPHX1ALDH1A1GAATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10363237-B2 | Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-30 | — | — | US | disclosed |
| US-20160256432-A1 | COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-09-08 | — | — | US | disclosed |
| EP-2916837-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014074421-A1 | PRODRUG BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8304403-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-06 | — | — | US | disclosed |
| CN-102459249-A | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases | EXELIXIS INC | 2012-05-16 | — | — | CN | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| CN-101312939-A | Heterocyclic cetp inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-11-26 | — | — | CN | disclosed |
| EP-1954668-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1689751-A1 | 5,7-DIAMINOPYRAZOLO¬4,3-D|PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | Pfizer Limited (GB) | 2006-08-16 | — | — | EP | disclosed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005049616-A1 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049616-A1 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | EPHX1 1130/4885ALDH1A1 2353/4885GAA 1018/4885 |
| US-10363237-B2 | Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase | NAAA, NAPEPLD, FAAH | EPHX1 234/4885ALDH1A1 2494/4885GAA 300/4885 |
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | EPHX1 585/4885ALDH1A1 851/4885GAA 55/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | EPHX1 1130/4885ALDH1A1 2353/4885GAA 1018/4885 |
| US-20160256432-A1 | COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE | NAAA, NAPEPLD, FAAH | EPHX1 234/4885ALDH1A1 2494/4885GAA 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.